When a Translational Project transitions from basic research into a product or service, it may result in the creation of a new company that is a spin-out from the IPD. Here is where you can learn about these companies and what they offer.
Since 2008 Arzeda has been harnessing the power of computational and synthetic biology to create new enzymes and chemical products that can compete on cost, performance and sustainability. The company was spun out from the University of Washington labs of Professor David Baker, who co-founded the company alongside Drs. Alexandre Zanghellini, Eric Althoff and Daniela Grabs-Röthlisberger to commercialize an innovative computational protein design technology based on the Rosetta software.
In partnership with Fortune 500 companies and industrial leaders, Arzeda has developed a portfolio of enzymes and specialty chemicals for polymers, advanced materials and health and nutrition products. Arzeda’s proprietary platform and validation process rapidly creates “cell factories” that can be used at industrial scales to solve problems and create opportunities that otherwise would be impossible.
More information is available online at www.arzeda.com and twitter.com/@ArzedaCo.
Cyrus Biotechnology is building an easy-to-use, but powerful, version of the Rosetta protein modeling and design software originally developed by Professor Baker, others at the IPD, and collaborating Universities. Rosetta has achieved a wide array of important “firsts” in protein modeling and design, and the IPD is pushing the way forward in protein design. However, the software remains very difficult to learn as well as to use. It also requires huge computational resources that many may not have access to. Cyrus is solving these problems with an entirely new Graphical User Interface custom-built for protein design, including automation of standard user procedures and huge amounts of compute “at-the-touch-of-a-button” on the cloud.
Read the announcement about their launch here.
Learn more at their website: http://cyrusbio.com/
Below is an image of Cyrus Bench CAD.
PvP Biologics is developing an oral enzyme for the treatment of celiac disease. Our mission is to develop a highly effective therapeutic product to reduce the burden of living with this disease. Toward this end, we are advancing a product candidate designed to break down the immunoreactive parts of gluten in the stomach and thereby avoid the painful symptoms and damage done in the small intestine from accidental gluten ingestion. The technology was invented at the Institute for Protein Design at the University of Washington and exclusively in-licensed by PvP Biologics. PvP Biologics has corporate offices in San Diego and research laboratories in Seattle.
Read the announcement about their spin-out here.
Visit their website at: https://pvpbio.com/
PvP Biologics was launched in 2015.
David Baker and Ingrid Swanson Pultz are co-founders.
Ingrid, along with Clancey Wolf, have left the IPD to break off with PvP.
From Ingrid Swanson Pultz:
My work involves engineering novel enzyme therapeutics to treat celiac disease. Celiac disease is characterized by intestinal inflammation caused by dietary gluten, which is a protein found in any food containing wheat, rye, or barley. Despite the clear medical need and its high prevalence (1% of the global population), there is currently no medical treatment for this disease. Using computational protein design, my group has engineered an enzyme, called KumaMax, that acts to rapidly and specifically break down the problematic gluten fragments in the stomach before they can reach the intestines and trigger the disease. KumaMax is meant to be taken in pill form before a meal, and shows great promise for the treatment of celiac disease.